Corporate Overview Dr Robert Scoffin CEO

© Re-Pharm >Clinical-stage company actively building a drug development pipeline >Focus on commercially valuable early stage assets: >Repositioned or repurposed compounds >Using a combination of biological understanding and Cresset tools >Targeted development to advanced pre-clinical/early clinical >Combination of Cresset technology and a very experienced team >Deep re-profiling expertise >Proven track record in getting re-profiled compounds to market launch >Extensive computational chemistry and cheminformatics knowledge Background Re-Pharm is a wholly-owned subsidiary of Cresset Biomolecular Discovery Ltd (Companies House: ). Re-Pharm has been created to focus on developing early- clinical assets for out-licensing. The Re-Pharm management team have a broad range of experience in drug discovery, molecular modelling and commercialisation of assets.

© Re-Pharm Advantages of Reprofiling >Greater knowledge of agent compared to classical NCE discovery >Existing toxicology, clinical safety, pharmacokinetics >Lower risk of failure >Faster development track >Create and maintain markets through new patents >Lowered R&D costs >Orphan indications >Better profitability >Examples of valuable re-profiled/re-purposed compounds >Doxycycline: antibiotic to periodontal disease and rosacea (MMP inhibitor) >Sildenafil: hypertension to ED (PDE5) >Raloxifene: Breast Cancer to Osteoporosis >Milnacipran: antidepressant to fibromyalgia >Seebri: glycopyrronium bromide for COPD – developed by Arakis/Sosei and Vectura – licensed to Novartis

© Re-Pharm Discovery Process In vitro hit identification In vivo confirmation Clinical proof of concept Therapy Concept Product Profile Database of Molecules Identify New Biology POC Data Chemical Enhancement Drug Delivery Enhancement Unmet medical need Identified IP position Commercial opportunity Pragmatic, product-focussed discovery

© Re-Pharm Management Team & Board >Rob Scoffin (CEO) Chemist by training with 24 years experience in developing businesses in the life sciences/drug discovery software and services market. >Alan Rothaul (CSO) Biologist by training. Over 30 years of drug company experience in major Pharma and biotech and founding VC based company, Serentis (raised £15M). Experienced in pre- clinical, clinical and regulatory areas. Has successfully been involved in drug reprofiling for~15 years and had a key involvement in the identification, development and licencing of NVA237 to Novartis. >Andy Vinter (Scientific Advisor) 40 years experience in pharmaceutical R&D, working with major companies and leading drug discovery groups, including Sir James Black at Smithkline & French. >David Bardsley (CBO) Microbiology background and 20 years of commercial experience in a variety of roles across the life sciences industry. An experienced management team and Board with an excellent external network

RP0217 NON-CONFIDENTIAL

© Re-Pharm Lead asset - RP0217 >Identified through ‘Smart Reprofiling™’ platform as having unexpected and potent anti-inflammatory activity in an in vitro biochemical assay >Old drug (1960’s) >No S.O.M. patent complications >API is readily available >Considerable clinical experience (>40 years) >Unexpected and unreported activity for a clinically and commercially desirable target >Comprehensively understood and acceptable safety profile and pharmacokinetics for both adult and paediatric use by the oral route >Repositioned from existing oral/systemic route of administration to topical >Standalone anti-inflammatory activity >Potent ‘steroid sparing’ synergy with standard glucocorticoids >Poor PK profile of oral formulations creates product opportunity for tissue- targeted delivery >Patentability, accepted target biology >Two GB patents granted – 1) topical ophthalmic indications – GB and 2) other topical indications – GB >A highly abridged development path - no need for systemic toxicology

© Re-Pharm Activity summary for RP0217 RP0217 alone RP nM Dex Selection of minimally active Dexamethasone conc. for synergy study Ex Vivo validation of activity Selection of minimally active Dexamethasone concentration for synergy study Clear synergy with glucocorticoid ~100 fold left shift in D/R curve Clear anti-inflammatory activity at very low concentrations of RP0217 in combination with steroid (threshold ~5x RP x Dexamethasone) Indication of “steroid sparing” activity-attractive profile for ocular allergy/inflammation In Vivo demonstration of activity in mouse model of Asthma 48 hour study on RP0217 standalone, compared to Fluticasone as reference standard Clear demonstration of activity

© Re-Pharm Investment Summary >Seeking funds to complete first-in-man POC of RP0217 and targeted out-licensing campaign - £1.5m >Fast-track early clinical (< 1 year) to robust POC in single indication >Additional funding for pipeline development - £1.0m >Further repositioned assets to be discovered and developed within identified pipeline of re-positioning opportunities >Creation of sustainable discovery ‘engine’ >Total funding of £2.5m on £10m ‘pre money’ valuation.

Dr Robert ScoffinDr Alan Rothaul Chief Executive OfficerChief Scientific Officer Dr David Bardsley Chief Business Officert: +44 (0)